Clinical Trial Update: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenalidomide versus observation in asymptomatic high-risk smoldering multiple myeloma; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Deposition Disease
• Smoldering Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Observation

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Light Chain Deposition Disease, Smoldering Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-05-18